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Highlights 
 
 Under hypoxia, the expression of CCR7 is elevated in both in vitro and in vivo models. 
 There is a correlation between HIF-1α and CCR7 in all head and neck clinical stages. 
 Hypoxia contributes to a metastatic phenotype in HNC by upregulating CCR7. 
 
  
Abstract  
Background: The chemokine receptor CCR7 is expressed on lymphocytes and dendritic cells 
and is responsible for trafficking of these cells in and out of secondary lymphoid organs. It 
has recently been shown that CCR7 expression is elevated in a number of cancers, including 
head and neck cancers, and that its expression correlates to lymph node (LN) metastasis. 
However, little is known about the factors that can induce CCR7 expression in head and neck 
cancers. 
Method: We compared the protein expression and functional responses of CCR7 under 
normoxia and hypoxia in head and neck cancer cell lines OSC-19, FaDu, SCC-4, A-253 and 
Detroit-562 cultured as monolayers, spheroids, and grown in vivo as xenografts in balb/c 
mice. In addition, we analysed the correlation between hypoxia marker HIF-1α and CCR7 
expression in a tissue microarray comprising 80 clinical samples with various stages and 
grades of malignant tumour and normal tissue.  
Results: Under hypoxia, the expression of CCR7 is elevated in both in vitro and in vivo 
models. Furthermore, in malignant tissue, a correlation is observed between hypoxia 
marker HIF-1α and CCR7 across all clinical stages. This correlation is also strong in early 
histological grade of tumours.  
Conclusion: Hypoxia plays a role in the regulation of the expression of CCR7 and it may 
contribute to the development of a metastatic phenotype in head and neck cancers through 
this axis. 
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Abbreviations: APES = 3-aminopropyltriethoxysilane; DAPI = 4',6-diamidino-2-phenylindole; 
HIF = hypoxia inducible factor; HNC = head and neck cancer; LDH-A = lactate dehydrogenase 
A; LN = lymph nodes; TMA = tissue microarrays.  
  
Introduction 
Tumours occurring in the anatomical regions of the head and neck are the sixth most 
common types of cancer worldwide, with over 500,000 new cases and over 350,000 deaths 
reported every year. [1] A particularly unwelcome hallmark of head and neck cancers is the 
high incidence of metastasis, particularly to regional lymph nodes. In fact, by the time of 
diagnosis, nearly half of head and neck cancers have already metastasised to neck lymph 
nodes and one in ten has metastasised to distant organs. [2] 
It is now well established that the chemotactic signalling axis involving chemokines CCL19 
and CCL21 acting on cell surface chemokine receptor CCR7 plays an important role in lymph 
node (LN) metastasis in a number of cancers. In normal physiology, CCR7 is expressed on 
lymphocytes and mature dendritic cells. The activation of CCR7 by CCL21 and CCL19 
released from the secondary lymphoid organs enables these cells to migrate against the 
chemokine gradient in and out of the lymph nodes. It has been hypothesised that cancer 
cells adopt this chemotactic axis, through upregulating the expression of CCR7; thus 
enabling them to invade the lymphatic system. [3] So far, the significance of the 
CCL19/CCL21-CCR7 axis in LN metastasis has been shown in pancreatic, [4] colorectal, [5] 
gastric, [6] melanoma [7], breast [8-9] and in the head and neck cancers. [10-21] In 
particular, these studies have shown that CCR7 expression is elevated in a wide range of oral 
and oropharyngeal clinical tumour tissue; that the elevation in CCR7 expression is associated 
with a metastatic phenotype [13] and correlates with the potential for cervical LN 
metastasis in a number of oral cancers; [12-18] and that CCR7 expression is a negative 
prognostic factor in many different head and neck cancers. [19-21] Moreover, intracellular 
pathways which are stimulated as a result of the activation of CCR7 are being identified,[10, 
22-26] and we are now beginning to gain an understanding of the mechanisms by which this 
axis contributes to the biology of the tumour cell.  
However, whilst the role of CCR7 axis in the expansion of head and neck cancers is apparent, 
with the exception of tumour–associated inflammation, [10] relatively little known of the 
factors which promote the upregulation of CCR7 expression on tumour cells.  
It is well established that as tumours grow, poor and irregular development of blood vessels 
leads to the emergence of regions within the tumour lacking in oxygen (hypoxia) and 
nutrients. Whilst the level of oxygenation in tumours can be quite varied, [27] more 
physiologically relevant, “severe” hypoxia in particular is known to have a wide ranging and 
profound influence on the tumour microenvironment, and to promote malignancy and 
metastasis in cancers, [28-29] including head and neck cancers [30,31] through a diverse 
number of pathways. Interestingly, one of those pathways involves the upregulation of 
chemotactic receptors, for example CXCR4, [32-36] on tumour cells which in turn increase 
their metastatic potential.  
In view of the recent evidence linking CCR7 expression with hypoxia in breast [35] and lung 
[36] cancers, we hypothesised that hypoxia may also be a factor in promoting CCR7 
expression in head and neck cancers. Therefore in this study we investigated whether CCR7 
expression correlates with the emergence of hypoxia in head and neck cancers.  
Materials and Methods 
Cells and cell culture 
All cell lines, except OSC-19, were obtained from European Collection of Cell Cultures 
(ECACC) UK, American Type Culture Collection (ATCC) or National Cancer Institute (NCI) 
Developmental Therapeutics Programme. OSC-19 was obtained from Japanese Collection of 
Research Bioresources (JCRB).  
Reagents and methods 
Recombinant CCL19 (catalogue number 361-MI-025) and CCL21 (catalogue number 366-6C-
025) were purchased from R&D Systems (Abingdon, UK). For flow cytometry, CCR7 Alexa 
Fluor® 488 conjugated anti-human CCR7 antibody (catalogue number 353205, Biolegend) 
(2:100 dilution) and the corresponding isotype matched control antibody (catalogue number 
400233, Biolegend) (2:100 dilution) were used. In Immunohistochemistry, deparaffinised 5 
μm-thick xenograft or tissue sections were incubated with CCR7 primary antibody (rabbit 
monoclonal IgG; Abcam, ab32527) (1:1000 dilution) for 1 h room temperature; whilst for 
HIF-1α (Anti-HIF-1α antibody, Abcam, catalogue number ab51608, 1:100 dilution) and Ki-67 
(1:100 dilution) detection, the antibodies were incubated overnight at 4°C. A vectastain ABC 
kit with 3,3-diaminobenzidine (DAB) as chromogen was used to visualise the proteins. For 
cellular immunofluorescence, cells were permeabilised using 0.1% Triton X-100 before 
treatment with CCR7 and Ki-67 primary antidodies and were detected using fluorescent 
secondary antibody (Alexa Fluor® 546 Donkey Anti-Rabbit IgG, life technologies, catalogue 
number A10040) for 1 h in the dark. For pimindazole detection, spheroids were treated with 
pimonidazole for 2 h prior to fixation in Bouin’s Solution and paraffin embedding. 
Hypoxyprobe™-1 Fitc conjugated antibody was added for 2 h at 37 °C. Cell nuclei were 
visualised using blue fluorescent dye DAPI. Scratch assays were performed in a 24 well plate 
with cells in media containing 2% serum. Images were captured at 0 h and an appropriate 
time to observe a significant difference between the two control experiments with and 
without added chemokine. These times were 24 h (SCC-4), 18 h (OSC-19), 24 h (FaDu), 42 h 
(DLD-1), 21 h (SW-480) and 14 h (PC-3) and migrated areas were measured using ImageJ 
software (NIH, USA). [37]  
Xenografts 
Balb/c immunodeficient nude female mice (Envigo, Loughborough, U.K.), aged between 6 
and 12 weeks were used. Throughout the study, all mice were housed in air-conditioned 
rooms in facilities approved by the United Kingdom Home Office to meet all current 
regulations and standards. All procedures were carried out under a United Kingdom Home 
Office Project License (PPL 40/3670). 1 x 106 Tumour cells in 100 μL of cell culture medium 
were injected into both abdominal flanks of the mouse, and tumour growth was then 
monitored using calliper measurements. Once tumours reached a volume of 150 mm3, mice 
were euthanised, and the tumours excised and fixed in 10% neutral buffered formalin for 24 
h before being processed for paraffin embedding. 5μm-thick tissue sections were then 
collected on to 3-aminopropyltriethoxysilane (APES) coated glass slides and allowed to dry 
at 37°C overnight. 
Tissue microarray 
Head and neck tissue microarrays slides (consecutive slides from block HN803c) were 
purchased from Insight Biotechnology Limited (Wembley, UK). The microarrays were 
prepared by the US Biomax Inc. (https://www.biomax.us/) and information on tumour 
extent (T), regional lymph nodes (N) and distant metastasis (M) was provided, along with 
patient clinical characteristics (see Supplementary Information S1). Biomax collects human 
tissues are under HIPPA approved protocols with the donor providing informed consent. 
Analysis 
General: All data is presented as the mean ± standard deviation of at least 3 independent 
experiments. Graph construction and statistical analysis was performed using GraphPad 
Prism 7.03. Differences among groups were assessed using the ANOVA test. Differences 
between two groups were assessed using a t test. P values were calculated to determine 
statistical significance of the results. *P < 0.05 and **P < 0.01 were deemed significant. 
Evaluation of CCR7 and HIF-1α staining in microarrays: H-score system [38] was used for the 
evaluation of the staining level of CCR7 and HIF-1α. Briefly, tumour cells were scored 
according to a pre agreed staining level intensity (Supplementary Information S2), and the 
H-score was subsequently generated by adding the percentage of strongly stained cell (x3), 
the percentage of moderately stained cell (×2), and the percentage of weakly stained cell 
(x1), over a possible range of 0–300. The scores were independently obtained by two expert 
pathologists (KDH and LM) and the correlation between the two independent scores was 
above 0.9. For statistical analysis, the mean of the two values was calculated and used. 
Statistical analyses for clinical samples between H-scores of CCR7 and HIF-1α for each 
clinical stage (1, 2, 3 and 4) and lymph node metastasis were performed using Pearson 
correlation test and the significance of the results is represented by P value. Statistical 
differences between the H-score for CCR7 or HIF-1α expression between tumour and non-
malignant cells were evaluated using Mann-Whitney U test. Association between high 
expression and clinical characteristics was evaluated using Fisher exact test. High expression 
levels were assigned for H-score ≥ 150 as the mid-way between the highest (300) and lowest 
(0) H-scores. *P < 0.05 and **P < 0.01 were deemed significant. Statistical tests on clinical 
samples were performed using Python 2.7 SciPy 0.19. 
Results and Discussions 
CCR7 is expressed in head and neck cancer cell lines and the receptor is functionally active 
We first set out to determine the expression of CCR7 in various head and neck cancer cell 
lines cultured as monolayers using immunofluorescence. We chose OSC-19 (metastatic 
tongue), FaDu (pharynx), SCC-4 (tongue), A-253 (submaxillary salivary gland) and Detroit-
562 (metastatic pharynx). For comparison, the expression of CCR7 in a number of other 
cancer cells lines was also assessed. In all five head and neck cancer cell lines, we detected 
the presence of CCR7. (Figure 1A) As the cells are permeabilised, antibody can access and 
react with both cytoplasmic and membranous CCR7. Indeed, we observed that in the head 
and neck cancer cell lines, expression of CCR7 was mostly membranous (except SCC-4), yet 
we observed cytoplasmic expression of CCR7 in both COLO205 and SW480 (not shown) 
colorectal cancer cell lines. (Figure 1A) 
 Figure 1: Expression and functional activity of CCR7 in cell lines: (A) Expression of CCR7 in head and neck 
cancer cell lines by immunofluorescence where blue represent staining for DAPI and red represent staining for 
CCR7. (B) Expression of CCR7 is detected in cancer cell lines by Western blot. (C) Expression of CCR7 in cancer 
cell lines by flow cytometry where the filled purple trace is the isotype control and cyan trace is the expression 
of CCR7. (D) Representative scratch assays. (E) Enhancement of cell motility in different cell lines upon 
treatment with CCL21 (100nM) and CCL19 (100nM) (n =3). Two tailed T test P values are considered 
statistically different when (P < 0.05). SCC4 ***p=0.0005 (CCL21), p=0.0647 (CCL19); OSC19 **p=0.026 
(CCL21), p=0.9686 (CCL19); FADU **p=0.0031 (CCL21), p=0.076 (CCL19); DLD1 p=0.9234 (CCL21), p=0.9064 
(CCL19); SW480 p=0.2838 (CCL21), p=0.6270 (CCL19); PC3 **p=0.0052 (CCL21), p=0.7871 (CCL19). 
 
Using Western blot technique, CCR7 was ubiquitously detected in a wide range of cancer 
cell lines (Figure 1B). To quantify the levels of CCR7, we used flow cytometry and measured 
the expression of membranous protein using isotype antibody as control for non-specific 
binding (Figure 1C). There was general agreement between Western blot and flow 
cytometry results, although interestingly, not in all cell lines (e.g. SW480 and COLO205). A 
similar observation was previously reported by Na et al. [39] which showed that defects in 
the signal peptide domain of CCR7 can lead to the accumulation of cytoplasmic protein, 
which is unable to translocate to the cell membrane. Since Western blot analysis is carried 
out on whole cell lysates, it may have overestimated the relative presence of membranous 
CCR7 receptor in SCC-4 cell line.  
In addition to demonstrating that the above head and neck cancer cell lines express CCR7, 
we also confirmed that the receptors are functionally active. In a scratch assay for OSC-19, 
FaDu and SCC-4, cell motility was increased in the presence of CCL21, a ligand for CCR7 
(Figure 1D). Interestingly, the cell lines’ response to CCL19 was less pronounced. This is 
consistent with reports from other laboratories that have shown CCL21 is better at inducing 
migration [40] and probably reflects the difference in the intracellular pathways activated by 
the two ligands. [41] In control experiments, the colon cell line DLD-1 and SW480 which 
express little CCR7, showed no increase in motility in the presence of CCL21 whilst CCR7 
expressing prostate PC-3 cell line did (Figure 1D, 1E).  
Whilst our results showed that head and neck cancer cell lines grown as monolayers express 
CCR7, we wanted to ensure that the CCR7 expression is maintained when the cells are 
grown as aggregates or as xenografts in vivo. There is evidence that cells can change their 
expression profiles when grown as multicellular spheroids or if xenoplanted in mice. For 
instance, ovarian cancer cell lines are known to change the expression pattern of several 
proteins. [42] In head and neck cancers similarly, the significance of tumour 
microenvironment to factors that influence disease progression has also been highlighted. 
[43] 
 
Figure 2: Expression and functional activity of CCR7 in multicellular spheroids: (A) Expression of CCR7 in a small 
spheroid where blue represents staining for DAPI and red represents staining for CCR7. Scale bar = 25 µm at 
20x magnification (B) Expression of CCR7 in a larger spheroid shows more red staining in the core. Scale bar = 
50 µm at 40x magnification (C) Presence of hypoxia in the core of larger spheroid is shown by 
immunofluorescence staining for pimonidazole adducts. (D) Proliferating rim of larger spheroid is shown by 
immunofluorescence staining for Ki-67. (E) Distribution of CCR7 as detected by immunofluorescence is uniform 
in smaller spheroid but elevated in the core of larger spheroid.  
 
To determine the expression of CCR7 in in vitro 3D models, OSC-19 cells were grown as 
multicellular spheroids, formalin fixed and embedded in paraffin before sections were taken 
and analysed by immunofluorescence. The results (Figure 2A) clearly show that CCR7 
expression is preserved in the cells within the spheroid. Furthermore, OSC-19, FaDu, A-253, 
and Detroit-562 cells were injected subcutaneously into mice and grown as tumours, 
excised, formalin fixed and embedded in paraffin before sections were taken and analysed 
by immunohistochemistry. Again, we observed that mostly membranous CCR7 expression is 
preserved in the cells within the different xenoplanted tumour tissues. The cytoplasmic 
expression of CCR7 was strongest in FaDu derived xenograft tissue. (Figure 3) Expression of 
CCR7 was also confirmed in clinical tissue (vide infra). 
 
Figure 3. Expression of CCR7 in xenografts derived from different head and neck cells lines Protein expression 
(brown) is identified by biotinylated-labelled antibody. Basophilic structure of cell (blue) was counter stained 
with haematoxylin solution. A, OSC-19; B, A-253; C, FaDu; D, Detroit-256; E, COLO205. Negative control for 
OSC-19 is also shown, F. Scale bar = 100 µm at 40x magnification 
 
CCR7 protein expression increases under hypoxia in both in vitro and in vivo models 
We next turned our attention to the role of hypoxia in CCR7 receptor expression. We 
quantitatively compared the cell surface expression of CCR7 in OSC-19 cells incubated under 
hypoxic and normoxic conditions. We found that all head and neck cancer cell lines, except 
SCC-4, increased their CCR7 expression under hypoxic conditions compared to cells 
incubated under normoxia. (Figure 4A-B) In particular, OSC-19 cells increased their CCR7 
expression by 2.5 fold as measured by flow cytometry. 
Figure 4. (A) Flow cytometry histograms showing relative expression of CCR7 under normaxia and under 
physiologic hypoxia (0.1% O2) (B) bar chart showing relative expression of CCR7 in different head and neck 
cancer cell lines. All expression levels are normalised to isotype (n = 3). Two tailed T test P values are 
considered statistically different when (P < 0.05): OSC19 **p=0.0067; FADU **p=0.0038; Detroit **p=0.0032; 
A253 *p=0.0351; SCC4 p=0.5537. (C) Levels of lactate dehydrogenase-A (LDH-A), a downstream indicator of 
HIF-1α mediated hypoxic response is elevated in OSC-19 cells under hypoxia. (D) Treatment of OSC-19 cells 
with CoCl2 induces HIF-1α. (E) Treatment of OSC-19 cells with CoCl2 results in an increase in CCR-7 expression 
(n=3), 100μM CoCl2 p= 0.2574, **, 200μM CoCl2 **p=0.0043. 
 
A well-known feature of hypoxia in cells is the induction of transcription factors HIF-1 and 
HIF-2, with the former being the more commonly studied, as well as downstream proteins 
such as lactate dehydrogenase A (LDH-A). [44,45] HIFs upregulate various cellular proteins in 
response to hypoxia, in order to compensate for the lack of available oxygen to the cell. 
[45,46] HIF-1 is comprised of two subunits: HIF-1ß, which is constitutively expressed and 
HIF-1α, levels of which are suppressed by oxygen sensing proteins under normoxia. Under 
hypoxia, however, intracellular levels of HIF-1α increase, which in complex with HIF-1ß leads 
to transcriptional changes in the cell. Although there are non-hypoxic mechanisms leading 
to the elevation of intracellular levels of HIF-1α, [47,48] detection of elevated HIF-1α or 
HIFs’ downstream proteins such as LDH-A [44] is generally considered to be an indicator of 
hypoxia. Indeed, we showed that in OSC-19 cells, levels of LDH-A are elevated under 
hypoxia. (Figure 4C) 
Stabilisation of HIF-1α can also be achieved by addition of CoCl2 to cell culture medium to 
mimic hypoxia. [49] So we next looked at the relationship between CCR7 and chemically 
induced (CoCl2) hypoxia. Indeed, addition of CoCl2 to OSC-19 cell culture medium, resulted 
in a dose dependent increase in HIF-1α. (Figure 4D) A parallel increase in levels of CCR7 
expression in the same cells was similarly detected by flow cytometry. (Figure 4E)  
Of course, whilst exposure of cell monolayers to low oxygen conditions, or the use of CoCl2 
to mimic hypoxia are useful models, neither realistically recapitulates the conditions 
experienced by cancer cells in tissue. In this context, multicellular spheroids provide a 
convenient in vitro tool which can better emulate the conditions experienced by cancer cells 
which are within a matrix. For example, since gas perfusion through cell layers is restricted, 
an oxygen gradient is established towards the core of spheroids which mimics hypoxia in 
tumours. Generally speaking 200 µm is considered the depth where oxygen levels fall to 
that seen in severe hypoxia (around 0.1% O2), therefore spheroids with a radius greater than 
that are expected to have a hypoxic core. [50]  
Indeed, analysis of the CCR7 expression in small and larger spheroids demonstrates that in 
the latter, the expression of the protein is higher in the hypoxic core compared to the 
oxygenated rim. When sections from a 230 μm diameter OSC-19 spheroid, which was 
formalin-fixed and embedded in paraffin, were stained for CCR7 by immunofluorescence, 
we observed a uniform distribution of fluorescence intensity. However, when sections from 
a 500 μm diameter OSC-19 spheroid were stained for CCR7 by immunofluorescence, the 
intensity of fluorescence in the core of the spheroids was relatively higher than in the 
periphery. (Figure 2B, 2E) To confirm the presence of hypoxia in the larger spheroid core, 
the spheroids were treated with pimonidazole [51] prior to fixing and embedding in 
paraffin. Cellular proteins which react with pimonidazole were visualised by 
immunofluorescence which clearly showed more fluorescence in the spheroid core 
confirming existence of hypoxia. (Figure 2C) In addition, a marker of proliferation, Ki-67 [52] 
was more strongly detected as predicted in the non-hypoxic rim of the spheroid. (Figure 2D) 
 
 
Figure 5. Staining of sequential sections from the A-253 xenografted issues for KI-67, (A); CCR7,(B); HIF-1α, (C); 
and hematoxylin/eosin (H&E), (D). Scale bar = 100 µm 
 
Having shown a correlation between hypoxia and CCR7 expression in 2D and 3D in vitro 
models, we next turned our attention to in vivo models. We had previously shown (above) 
that head and neck cancer cell lines maintain expression of CCR7 when grown as xenografts 
in mice. Therefore, we set out to analyse the correlation between the expression of CCR7, 
and hypoxia in xenotransplanted tissue from head and neck cancer cell line A-253 as an 
example. (Figure 5) Sequential tissue sections were immunolabelled for CCR7, HIF-1α as an 
indicator of hypoxia, Ki-67 as a marker for proliferating cells, as well staining with 
haematoxylin and eosin (H&E) to assess tumour morphology. (Figure 5A) Analysis of the 
tissue sections showed immunolocalisation of CCR7 across the tumour, but labelling 
intensity was higher in the vicinity of the hypoxic regions as indicated by HIF-1α nuclear 
localisation. (Figure 5B and C) The elevation of CCR7 in the hypoxic/necrotic region of the 
xenografted tumour was also confirmed with H&E staining. (Figure 5B and D)  
Correlation between CCR7 protein expression with tumour grade and HIF-1α in clinical 
tissue 
Having shown a correlation between CCR7 and HIF-1α in vitro and in vivo, we turned our 
attention to the analysis of the correlation between the two in clinical tissue. Consecutive 
slides form tissue microarrays (TMAs) with 80 patient cores (Table 1 and Supplementary 
Information S1) were labelled with HIF-1α and CCR7, and were scored independently for 
both using the H-score system, with the correlation (R) between the two independent 
scorers being >0.9. We first established that CCR7 expression is elevated in malignant 
tissues compared to non-malignant samples using the Mann-Whitney U test (P = 0.007). 
(Figure 6A) In contrast, we did not observe a correlation between malignancy and HIF-1α 
expression. Interestingly, we found a correlation between higher expression of CCR7 (H-
score > 150) with the clinical stage of cancer, and this is also strong in stage 1 compared to 
non-malignant tissues. (Table 1) In contrast, we found no correlation between higher 
expression of HIF-1α (H-score > 150) and any clinical stages (Table 1). Similarly, we observed 
an association between expression of both CCR7 and HIF-1α in histological grade 1 tumours 
compared with non-malignant tissue, with P = 0.0001 and 0.018 respectively for CCR7 and 
HIF-1α. (Table 2)  
 
 CCR7  HIF-1α  
 Low (n) High (n) P Low (n) High (n) P 
non-malignant 9 2  9 2  
Stage 1 0 6 P=0.002** 2 4 P=0.1 
Stage 2 12 11 P=0.14 18 5 P=1 
Stage 3 8 11 P=0.06 17 2 P=0.6 
Stage 4 5 8 P=0.05* 10 3 P=1 
LN metastasis 3 5 P=0.07 6 2 P=1 
 
Table 1: Association of high expression of CCR7 or HIF-1α with head and neck cancer in different stages of the 
disease.  
  
Figure 6. (A) Comparison of the range of H-score for CCR7 and HIF-1α between non-malignant and malignant 
tissue samples show that CCR7 expression is elevated in malignant compared to non-malignant tissue (red line 
represent median value of H-scores in each case). (B-E) Analysis of the relative expression of CCR7 and HIF-1α 
in each individual sample shows a correlation between the two for each clinical stage as well as for lymph node 
metastases (F-I). Analysis of the relative expression of CCR7 and HIF-1α in each individual sample showed a 
correlation between the two in individual samples for all grades; with the highest correlation observed in 
grade 1. 
 
An analysis of the relative expression of CCR7 and HIF-1α in each individual tissue sample 
revealed a correlation (R) between the two for each clinical stage (Figure 6B-E), as well as 
for lymph node metastases (Figure 6F). Similarly, we observed a correlation between the 
relative expression of CCR7 and HIF-1α in individual samples for all grades; with the highest 
correlation observed in grade 1 (R=0.68, P=0.004) (Figure 6G-I) suggesting that the level of 
differentiation of tumours may be relevant for the relationship between CCR7 and HIF-1α. 
Our findings are concordant with two previous studies in breast [35] and lung [36] cancer 
which also reported a correlation between the CCR7 and HIF-1α expression, and studies 
which associate another important chemokine receptor, CXCR4, to hypoxia and HIF-1α [31, 
32]. They support the hypothesis that hypoxia, particularly in the early stages of tumour 
development, may be involved in promoting the invasion and migration of head and neck 
cancer cells through CCR7 axis. 
 
Grade CCR7  HIF-1α  
 Low 
(n) 
High 
(n) 
 
P 
Low 
(n) 
High 
(n) 
 
P 
non-malignant 9 2  9 2  
Grade 1 1 15 P=0.0001** 5 11 P=0.018* 
Grade 2 11 15 P=0.26 23 3 P=0.6 
Grade 3 9 7 P=0.23 16 0 P=0.16 
 
Table 2: Association of high expression of CCR7 or HIF-1α with head and neck cancer in different histological 
grades of the disease.  
 
Conclusions 
We have shown that in 2D monolayers, 3D multicellular spheroids, xenotransplanted cells 
and clinical tissue, there is a positive correlation between hypoxia and CCR7 expression. In 
clinical samples in particular, the correlation between hypoxia and CCR7 in the all clinical 
stages suggests the two are related.  
Hypoxia is a key feature of head and neck tumours, is widely observed in the clinical setting, 
and is associated with resistance to radiotherapy, reduced therapeutic response, and a 
poorer clinical outcome. [53,54] The role of hypoxia in head and neck tumours is 
undoubtedly complex and acts through multiple pathways. However, understanding the 
mechanisms by which hypoxia can promote the tumour progression, provides opportunities 
to combat its negative impact on the disease. [55-59] Our results strongly associate hypoxia 
with the emergence of the expression of CCR7, complementing earlier observations by 
Ferris who has shown that release of CCL21 and CCL19 into the tumour microenvironment 
by invading lymphocytes can increase CCR7 expression through an autocrine loop. [10] 
Taken together, both results confirm a central role for the CCR7 axis in head and neck 
tumours. In addition, in view of CCR7 being a negative prognostic factor for lymph node (LN) 
metastasis, [19-21] our findings suggests that hypoxia is likely to contribute to the 
development of a metastatic phenotype in head and neck cancers through upregulation of 
CCR7 signalling. Therefore, inhibition of CCR7 signalling by small molecule CCR7 antagonists 
[60] may prove to be a very useful adjunct therapy to be used in combination with existing 
treatments for head and neck cancers.  
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Supplementary Information S1: Characteristics of microarrays clinical sample 
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TNM  type 
A1 F 61 Oral cavity Squamous cell carcinoma of palate 1 I T1N0M0 Malignant 
A2 M 61 Lip Squamous cell carcinoma of lower lip 1 I T1N0M0 Malignant 
A3 M 77 Lip Squamous cell carcinoma of lower lip 1 I T1N0M0 Malignant 
A4 F 75 Oral cavity Squamous cell carcinoma of upper jaw 1 I T1N0M0 Malignant 
A5 M 67 Oral cavity Squamous cell carcinoma of right palate 1 II T2N0M0 Malignant 
A6 M 50 Tongue Squamous cell carcinoma of root of tongue 1 III T3N1M0 Malignant 
A7 M 66 Pharynx Squamous cell carcinoma of pharynx 1 IVA T3N2M0 Malignant 
A8 M 49 Gingiva Squamous cell carcinoma of right gingiva 1 IVA T4N0M0 Malignant 
A9 M 55 Pharynx Squamous cell carcinoma of epiglottis 1 IVA T4N0M0 Malignant 
A10 M 57 Pharynx Squamous cell carcinoma of oropharynx 1 IV T4N0M0 Malignant 
B1 M 74 Nose Squamous cell carcinoma of root of nose 2 II T2N0M0 Malignant 
B2 M 90 Cheek Squamous cell carcinoma of cheek - II T2N0M0 Malignant 
B3 M 72 Larynx Squamous cell carcinoma of larynx 1 II T2N0M0 Malignant 
B4 F 61 Oral cavity Squamous cell carcinoma of right mandible 1 II T2N0M0 Malignant 
B5 M 50 Larynx Squamous cell carcinoma of larynx 1 III T2N1M0 Malignant 
B6 M 67 Larynx Squamous cell carcinoma of larynx 2 III T3N1M0 Malignant 
B7 M 58 Larynx Squamous cell carcinoma of larynx 2 III T3N1M1 Malignant 
B8 M 52 Nose Squamous cell carcinoma of nasopharynx 2 I T1N0M0 Malignant 
B9 M 60 Tongue Squamous cell carcinoma of tongue 2 II T2N0M0 Malignant 
B10 M 60 Tongue Squamous cell carcinoma of tongue 2 II T2N0M0 Malignant 
C1 M 67 Larynx Squamous cell carcinoma of throat 3 II T2N0M0 Malignant 
C2 M 48 Cheek Squamous cell carcinoma of cheek 1 II T2N0M0 Malignant 
C3 M 70 Oral cavity Squamous cell carcinoma of right mandible 2 II T2N0M0 Malignant 
C4 M 43 Oral cavity Squamous cell carcinoma of right mandible 2 II T2N0M0 Malignant 
C5 M 56 Pharynx Squamous cell carcinoma of pharynx 2 II T2N0M0 Malignant 
C6 M 45 Cheek Squamous cell carcinoma of right cheek - II T2N0M0 Malignant 
C7 M 47 Larynx Squamous cell carcinoma of larynx 2 II T2N0M0 Malignant 
C8 M 61 Pharynx Squamous cell carcinoma of epiglottis - II T2N0M0 Malignant 
C9 M 50 Larynx Squamous cell carcinoma of larynx 2 II T2N0M0 Malignant 
C10 F 38 Lip Squamous cell carcinoma of lower lip 2 II T2N0M0 Malignant 
D1 M 47 Larynx Squamous cell carcinoma of larynx 3 III T2N1M0 Malignant 
D2 F 50 Pharynx Squamous cell carcinoma of hypopharynx 2 III T2N1M0 Malignant 
D3 M 71 Pharynx Squamous cell carcinoma of hypopharynx 2 III T2N1M0 Malignant 
D4 M 44 Pharynx Squamous cell carcinoma of hypopharynx 2 III T2N1M0 Malignant 
D5 M 61 Pharynx Squamous cell carcinoma of epiglottis 2 III T2N1M0 Malignant 
D6 M 54 Oral cavity Squamous cell carcinoma of left upper jaw 2 III T3N0M0 Malignant 
D7 M 61 Pharynx Squamous cell carcinoma of hypopharynx 3 III T3N0M0 Malignant 
D8 M 58 Larynx Squamous cell carcinoma of larynx 3 III T3N0M0 Malignant 
   
D9 M 63 Pharynx Squamous cell carcinoma of epiglottis 2 III T3N1M0 Malignant 
D10 M 71 Pharynx Squamous cell carcinoma of epiglottis 3 III T3N1M0 Malignant 
E1 M 51 Pharynx Squamous cell carcinoma of left pharynx 2 III T3N1M0 Malignant 
E2 M 55 Larynx Squamous cell carcinoma of larynx 2 III T3N1M0 Malignant 
E3 M 75 Oral cavity Squamous cell carcinoma of maxillary sinus 2 IV T4N0M0 Malignant 
E4 M 56 Pharynx Squamous cell carcinoma of epiglottis 1 IVA T4N0M0 Malignant 
E5 M 57 Larynx Squamous cell carcinoma of larynx - IVA T4N0M0 Malignant 
E6 M 49 Larynx Squamous cell carcinoma of larynx 3 IVA T4N1M0 Malignant 
E7 F 69 Cheek Squamous cell carcinoma of right cheek 2 I T2N0M0 Malignant 
E8 M 29 Larynx Squamous cell carcinoma of larynx - II T2N0M0 Malignant 
E9 F 56 Lip Squamous cell carcinoma of oral lip 2 II T2N0M0 Malignant 
E10 M 50 Oral cavity Squamous cell carcinoma of maxillary sinus 2 II T2N0M0 Malignant 
F1 M 50 Tongue Squamous cell carcinoma of tongue 3 II T2N0M0 Malignant 
F2 M 64 Larynx Squamous cell carcinoma of larynx 3 II T2N0M0 Malignant 
F3 M 49 Larynx Squamous cell carcinoma of larynx 3 III T2N1M0 Malignant 
F4 F 42 Nose Squamous cell carcinoma of nasal sinus 3 III T3N0M0 Malignant 
F5 M 50 Larynx Squamous cell carcinoma of larynx 3 III T3N1M0 Malignant 
F6 M 58 Larynx Squamous cell carcinoma of larynx 3 IV T2N2N0 Malignant 
F7 M 75 Nose Squamous cell carcinoma of nasal sinus 3 IV T4N0M0 Malignant 
F8 M 48 Pharynx Squamous cell carcinoma of hypopharynx 3 IV T4N0M0 Malignant 
F9 M 74 Pharynx Squamous cell carcinoma of hypopharynx - IV T4N0M0 Malignant 
F10 M 65 Larynx Squamous cell carcinoma of larynx 3 IV T3N2M0 Malignant 
G1 F 32 Oral cavity Carcinoma sarcomatodes of maxillary sinus - II T2N0M0 Malignant 
G2 F 40 Lymph node Metastatic mucoepidermoid carcinoma - - - Metastasis 
G3 M 67 Lymph node Metastatic mucoepidermoid carcinoma - - - Metastasis 
G4 M 45 Lymph node Metastatic mucoepidermoid carcinoma - - - Metastasis 
G5 M 47 Lymph node Metastatic squamous cell carcinoma 1 - - Metastasis 
G6 M 48 Lymph node Metastatic squamous cell carcinoma 2 - - Metastasis 
G7 M 53 Lymph node Metastatic squamous cell carcinoma 3 - - Metastasis 
G8 F 45 Lymph node Metastatic squamous cell carcinoma 2 - - Metastasis 
G9 F 52 Lymph node Metastatic acinic cell carcinoma - - - Metastasis 
G10 M 38 Tongue Adjacent normal tongue tissue - - - NAT 
H1 M 28 Tongue Tongue tissue - - - Normal 
H2 F 27 Tongue Tongue tissue - - - Normal 
H3 M 48 Tongue Tongue tissue - - - Normal 
H4 F 42 Tongue Adjacent normal tongue tissue - - - NAT 
H5 F 15 Tongue Tongue tissue - - - Normal 
H6 F 19 Tongue Tongue tissue - - - Normal 
H7 M 35 Tongue Tongue tissue - - - Normal 
H8 F 18 Tongue Tongue tissue - - - Normal 
H9 F 19 Tongue Tongue tissue - - - Normal 
H10 M 28 Tongue Tongue tissue - - - Normal 
Supplementary Information S2: Representative images from immunohistochemical staining 
of the tumour microarray for expression level of CCR7 (A-D) and HIF-1α (E-H) in head and 
neck tumours. (A and E) strong staining; (B and F) medium staining; (C and G) weak staining; 
(D and H) control.   
 
 
